Gammaras Ingredients and Usage

The active ingredient is Human Normal Immunoglobulin containing primarily IgG with a broad spectrum of antibodies against bacterial and viral antigens. It is administered as a slow intravenous infusion with the initial rate of 0.5-1 mg/kg/min, gradually increasing as tolerated.

Gammaras is clinically indicated for:

• Primary immunodeficiency syndromes
• Secondary immunodeficiencies with impaired antibody production
• Immune thrombocytopenic purpura (ITP)
• Guillain-Barré syndrome and other neuroimmunological disorders
• Kawasaki disease and various autoimmune conditions

How Does Gammaras Work?

Gammaras provides immunomodulatory effects through multiple mechanisms:

1. Antibody Replacement: Provides broad-spectrum IgG antibodies for immunodeficient patients
2. Fc Receptor Blockade: Blocks Fc receptors on macrophages in immune thrombocytopenia
3. Anti-inflammatory Action: Modulates complement activation and cytokine production
4. Autoantibody Neutralization: Neutralizes pathogenic autoantibodies in autoimmune diseases

Gammaras Side Effects and Warnings

Common side effects include headache, fever, chills, myalgia, and infusion site reactions. Most reactions are mild and occur during or shortly after infusion.

Serious Considerations

1. Anaphylaxis: May cause severe hypersensitivity reactions, especially in IgA-deficient patients
2. Thromboembolic Events: Increased risk of thrombosis, stroke, and myocardial infarction
3. Aseptic Meningitis: Can cause aseptic meningitis syndrome within 72 hours of infusion
4. Renal Impairment: May cause acute renal failure, especially with sucrose-containing products
5. Hemolytic Reactions: Can cause hemolysis due to passive transfer of blood group antibodies

Gammaras Storage Conditions

Gammaras Injection requires strict storage conditions:

• Store at 2°C to 8°C in refrigerator
• Do not freeze – protect from light
• Keep in original carton until use
• Use immediately after opening
• Do not use if cloudy, discolored, or contains particles